HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $400 | -34.9% | 11,087 | -31.1% | 0.00% | -25.0% |
| Q1 2023 | $614 | -6.8% | 16,087 | +38.9% | 0.00% | -20.0% |
| Q4 2022 | $659 | -99.9% | 11,581 | -62.4% | 0.01% | -44.4% |
| Q3 2022 | $1,217,000 | -48.2% | 30,774 | -42.4% | 0.01% | -47.1% |
| Q2 2022 | $2,350,000 | +10.3% | 53,398 | 0.0% | 0.02% | +41.7% |
| Q1 2022 | $2,130,000 | -83.6% | 53,398 | -83.5% | 0.01% | -82.1% |
| Q4 2021 | $13,027,000 | -7.0% | 323,083 | -6.2% | 0.07% | -13.0% |
| Q3 2021 | $14,006,000 | +57.6% | 344,302 | +75.9% | 0.08% | +40.0% |
| Q2 2021 | $8,887,000 | +8.9% | 195,714 | 0.0% | 0.06% | +1.9% |
| Q1 2021 | $8,159,000 | +212.6% | 195,714 | +220.3% | 0.05% | +200.0% |
| Q4 2020 | $2,610,000 | +23.2% | 61,100 | -24.2% | 0.02% | +20.0% |
| Q3 2020 | $2,118,000 | +144.6% | 80,600 | +149.5% | 0.02% | +114.3% |
| Q2 2020 | $866,000 | – | 32,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |